The deals that move
modern medicine.
Inside the boardrooms and term sheets behind healthcare's biggest M&A deals, IPOs, and venture rounds.
In drug development, Phase 3 is the trial that decides everything - molecule becomes medicine, or write-off. Every deal in healthcare carries the same weight. Capital meets conviction. One outcome reshapes the industry.
Runs Pylon Partners, an investment firm focused on emerging tech. Former consumer private equity investor based out of Hong Kong.
Phase Three is his lens into the people reshaping how medicine gets funded, built, and brought to market.